The UK-China Business Council meeting is held at the Great Hall of the People in Beijing, on Jan 29, 2026. [Photo/sinopharm.com]

The UK-China Business Council meeting was held at the Great Hall of the People in Beijing, on Jan 29, with over 110 representatives from Chinese and British enterprises and institutions in attendance. Bai Zhongquan, chairman of China National Pharmaceutical Group Co Ltd (Sinopharm), was invited to participate in the meeting.

Bai Zhongquan, chairman of Sinopharm, delivers a speech on behalf of China's pharmaceutical and healthcare enterprises during the corporate discussion session. [Photo/sinopharm.com]

During the corporate discussion session, Bai delivered a speech on behalf of China's pharmaceutical and healthcare enterprises, saying that Sinopharm, as a “national team” and leading force in the industry, possesses China's largest commercial network for pharmaceuticals and medical devices, and is capable of delivering products nationwide.

The group also has the most comprehensive pharmaceutical manufacturing system in the country, covering key sectors such as biopharmaceuticals, modern traditional Chinese medicine (TCM), and chemical pharmaceuticals. This positions the group as a backbone for ensuring the supply of vaccines, blood products, and TCM products, he added.

Bai said that Sinopharm, with the longest pharmaceutical and healthcare industry chain in China, operates in a wide range of sectors including medical care, wellness, pharmaceutical exhibitions, engineering design, and pharmaceutical investment, providing complete health services to the public. It has maintained close and stable cooperation with UK companies such as AstraZeneca, GSK plc, Haleon, Boots, and RX, as well as renowned research institutions like Oxford University. The group is consistently working to connect UK innovations directly with China's industrialization and market capabilities.

Since its establishment in 2018, the UK-China Business Council has played a significant role in building bridges of trust and cooperation between Chinese and British enterprises, deepening economic and trade ties, supporting multilateral trade systems, and promoting practical cooperation across sectors under the guidance of China's Ministry of Commerce.

As a Chinese member of the council, Sinopharm is committed to working with stakeholders on both sides to enrich and expand bilateral dialogue in the pharmaceutical and healthcare field, advance mutual recognition of standards, and foster international scientific and technological collaboration.

By strengthening these ties, the group strives to contribute to the health and well-being of people worldwide and create new and greater benefits for both China and the UK.